US 10010587
IL-2Rβ-selective agonists in combination with an anti-CTLA-4 antibody or an anti-PD-1 antibody
granted A61KA61K2039/505A61K2300/00
Quick answer
US patent 10010587 (IL-2Rβ-selective agonists in combination with an anti-CTLA-4 antibody or an anti-PD-1 antibody) held by Nektar Therapeutics expires Mon Jun 28 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Nektar Therapeutics
- Grant date
- Tue Jul 03 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 28 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 15
- CPC classes
- A61K, A61K2039/505, A61K2300/00, A61K38/2013, A61K39/39541